Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | GRIN2B | Q13224 | 8/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | BCL9 | O00512 | 1/20 | 0.40 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.40 |
| ▸ | F13A1 | P00488 | 1/20 | 0.39 |
| ▸ | TGM2 | P21980 | 1/20 | 0.39 |
| ▸ | TGM1 | P22735 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14500775 | 1.00 | MEN1 (0.44) | MEN1KMT2AGRIN2BALDH1A1BCL9 | |
| SCHEMBL8303062 | 0.89 | GRIN2B (0.43) | MEN1KMT2AGRIN2BBCL9CTNNB1 | |
| SCHEMBL13711175 | 0.88 | GAA (0.37) | ALDH1A1 | |
| SCHEMBL13712736 | 0.85 | GRIN2B (0.44) | MEN1KMT2AGRIN2BALDH1A1BCL9 | |
| SCHEMBL13712731 | 0.85 | GRIN2B (0.44) | MEN1KMT2AGRIN2BALDH1A1BCL9 | |
| SCHEMBL14099398 | 0.84 | ALDH1A1 (0.44) | MEN1KMT2AALDH1A1 | |
| SCHEMBL14501401 | 0.82 | ALDH1A1 (0.34) | ALDH1A1 | |
| SCHEMBL4484409 | 0.81 | GRIN2B (0.47) | MEN1KMT2AGRIN2BALDH1A1BCL9 | |
| SCHEMBL4460100 | 0.80 | ESR2 (0.36) | MEN1KMT2AALDH1A1 | |
| SCHEMBL4460095 | 0.80 | ESR2 (0.36) | MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7592360-B2 | Parkinson's disease, Alzheimer's disease, migraine, epilepsy, and pain | MERCK & CO., INC. (US) | 2009-09-22 | — | — | US | disclosed |
| US-20070149568-A1 | N-substituted nonaryl-heterocyclic nmda/nr2b antagonists | MERCK SHARP & DOHME LLC | 2007-06-28 | — | — | US | disclosed |
| US-20070149568-A1 | N-substituted nonaryl-heterocyclic nmda/nr2b antagonists | MERCK SHARP & DOHME LLC | 2007-06-28 | — | — | US | disclosed |
| WO-2004108705-A1 | 3-FLUORO-PIPERIDINES AS NMDA/NR2B ANTAGONISTS | MERCK & CO., INC. (US) | 2004-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149568-A1 | N-substituted nonaryl-heterocyclic nmda/nr2b antagonists | GRIN2B, GRIN1, GRIN2A | MEN1 1344/4885KMT2A 1463/4885GRIN2B 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.